Accolade (NASDAQ:ACCD) Announces Earnings Results

Accolade (NASDAQ:ACCD) announced its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01, Briefing.com reports. The firm had revenue of $124.80 million during the quarter, compared to analyst estimates of $123.91 million. Accolade had a negative return on equity of 22.57% and a negative net margin of 24.09%. The business’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same period last year, the company posted ($0.42) EPS. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Performance

NASDAQ ACCD traded down $1.30 during trading on Friday, hitting $7.89. The company’s stock had a trading volume of 1,491,193 shares, compared to its average volume of 585,879. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average price of $9.66 and a 200 day moving average price of $9.91. The firm has a market cap of $610.76 million, a P/E ratio of -5.93 and a beta of 2.08. Accolade has a 52 week low of $6.33 and a 52 week high of $17.00.

Analyst Upgrades and Downgrades

ACCD has been the subject of several research reports. Canaccord Genuity Group reduced their price target on Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday. Morgan Stanley reduced their price target on Accolade from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday. Truist Financial reduced their price target on Accolade from $16.00 to $14.00 and set a “buy” rating for the company in a report on Friday. Barclays reduced their price target on Accolade from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Stifel Nicolaus reduced their price target on Accolade from $15.00 to $13.00 and set a “buy” rating for the company in a report on Monday, April 22nd. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.80.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.